Urinary Excretion of Interleukin-6 in Pediatric IgA Nephropathy Patients
- *Corresponding Author:
- Katsuyoshi Kanemoto
Department of Pediatrics
National Hospital Organization Chiba-East Hospital
763 Nitona, Chuo-ku
Chiba 260-8712, Japan
E-mail: [email protected]
Received Date: January 17, 2014; Accepted Date: February 18, 2014; Published Date: February 25, 2014
Citation: Kanemoto K, Matsumura R, Anzai M, Matsumura C, Kurayama H (2014) Urinary Excretion of Interleukin-6 in Pediatric IgA Nephropathy Patients. J Nephrol Therapeutic S11:004. doi:10.4172/2161-0959.S11-004
Copyright: © 2014 Kanemoto K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: Urinary excretion of interleukin-6 (U-IL6) has been reported to be elevated and to represent the disease activity in adult IgA nephropathy (IgAN). We investigated the significance and the utility of U-IL6 activity in pediatric IgAN patients. Methods: We evaluated 55 pediatric IgAN patients (4–18 years; mean age, 10.7 years) and 53 healthy controls from 2007 to 2012. The U-IL6 concentrations (pg/mg creatinine) were estimated by ELISA at the time of renal biopsy and after 6 months of prednisolone therapy for IgAN. In addition, we evaluated the correlations between the U-IL6 level and clinic pathological parameters of IgAN. To elucidate the usefulness for early diagnosis of IgAN, we investigated U-IL6 in 45 asymptomatic hematuria (ASH) children who were diagnosed by school urine screening program. Results: U-IL6 activity was significantly higher in IgAN patients than in healthy controls and ASH children (p<0.01). In addition, U-IL6 was significantly decreased after 6 months of prednisolone therapy (p<0.01). With regard to the clinicopathological parameters, U-IL6 activity was correlated with degree of proteinuria (p<0.01, r=0.72), hematuria (p<0.01, r=0.54), urinary podocyte score (p<0.01, r=0.59), mesangial cell proliferation (p<0.05), endocapillary proliferation (p<0.01), and crescent formation (p<0.05). Interestingly, five children who transited to IgAN from ASH during the observation period showed high U-IL6 levels (p<0.01). Conclusions: The present results also suggest that U-IL6 represents the disease activity in pediatric IgAN patients. We consider that it is important to evaluate U-IL6 in patients with ASH detected by school urinary screening program for early detection and prevention of unrecognized progression of IgAN.